

Not for release to US wire services or distribution in the United States

12 June 2024

Dear Shareholder

NOTICE TO INELIGIBLE SHAREHOLDERS OF ACCELERATED NON-RENOUNCEABLE ENTITLEMENT OFFER

On 4 June 2024, Genetic Signatures Limited (**Genetic Signatures** or the **Company**) announced that it is undertaking a capital raising of up to approximately \$30 million (before costs) through the issue of new fully paid ordinary shares at an offer price of \$0.75 per share (**New Shares**), comprising:

- (a) a placement of New Shares to sophisticated and professional investors to raise up to approximately \$6 million (before costs); and
- (b) a fully underwritten pro rata accelerated non-renounceable entitlement offer to raise approximately \$24 million (before costs), whereby eligible shareholders will be invited to subscribe for 1 New Share for every 5.82 existing shares held on the record date (**Entitlement Offer**).

The Entitlement Offer is being made without a prospectus or product disclosure document in accordance with section 708AA of the *Corporations Act 2001* (Cth) (**Corporations Act**) as modified by the *Australian Securities and Investments Commission (ASIC) Legislative Instrument (Non-Traditional Rights Issues) 2016/84*.

The Entitlement Offer comprises an offer to eligible institutional shareholders (**Institutional Entitlement Offer**) and an offer to Eligible Retail Shareholders (as defined below) (**Retail Entitlement Offer**) to participate on the same terms.

The Institutional Entitlement Offer has already closed and the results have been announced to the ASX.

The Company has today lodged a retail entitlement offer booklet with the ASX (available to view on the ASX website at <https://www.asx.com.au/markets/company/gss> and the Company's website <https://geneticsignatures.com/investors> which sets out further details in respect of the Retail Entitlement Offer.

Eligibility criteria

The Company has determined, pursuant to ASX Listing Rule 7.7.1(a) and section 9A of the Corporations Act, that it would be unreasonable to make offers to shareholders in all countries outside Australia and New Zealand in connection with the Retail Entitlement Offer. This is due to the legal and regulatory requirements in countries other than Australia and New Zealand and the potential costs to the Company of complying with these requirements, compared with the relatively small number of shareholders in those countries, the relatively small number of existing shares they hold and the relatively low value of new shares to which those shareholders would otherwise be entitled to subscribe for.

Shareholders who are eligible to participate in the Retail Entitlement Offer are shareholders who:

- are registered as the holder of existing shares as at **7.00pm (Sydney time) on Thursday, 6 June 2024 (Record Date)**;
- have a registered address on the Company's share register that is in Australia or New Zealand; and
- were not invited to participate in the Institutional Entitlement Offer or treated as an ineligible institutional shareholder for that purpose.

Unfortunately, according to our records, you do not satisfy the eligibility criteria for an Eligible Retail Shareholder as stated above. Accordingly, in compliance with ASX Listing Rule 7.7.1(b) and section 9A of the Corporations Act, the Company wishes to advise you that it will not be extending the Retail Entitlement Offer to you and you will not be able to subscribe for New Shares under the Retail Entitlement Offer.

Treatment of ineligible shareholders

Ineligible shareholders are not entitled to participate in the Entitlement Offer.

As the Entitlement Offer is non-renounceable, no amount will be payable by or to you. You will not receive any value in respect of any new Shares that would have been offered to you if you were an Eligible Shareholder, and your shareholding in the Company will be diluted as a result of the Entitlement Offer.

No action required

This notice is to inform you about the Retail Entitlement Offer. This notice is not an offer to issue new shares to you, nor an invitation for you to apply for new shares. You are not required to do anything in response to this notice.

On behalf of the Board and management of the Company, we regret that you are not eligible to participate in the Entitlement Offer but thank you for your continued support.

If you have any further questions, you should contact your stockbroker, accountant or other professional adviser.

Authorised for release by the Board.

For more information, please contact:

Mr Karl Pechmann
Company Secretary
Genetic Signatures Limited
Email: investor@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its EasyScreen™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.
